Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis

Journal of Investigative Dermatology

Volumn 128, Issue 8, 2008, Pages 1925-1929

  Warren, Richard B ^a   Smith, Rhodri Ll ^a   Campalani, Emanuela ^b   Eyre, Steve ^a   Smith, Catherine H ^b   Barker, Jonathan N W N ^b   Worthington, Jane ^a   Griffiths, Christopher E M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER C1; ADENOSINE RECEPTOR; BREAST CANCER RESISTANCE PROTEIN; DNA; METHOTREXATE;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLELE; ARTICLE; BIOINFORMATICS; CHILD; CONFIDENCE INTERVAL; DIARRHEA; DRUG EFFICACY; FEMALE; GENE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HAPLOTYPE MAP; HUMAN; HYPOTHESIS; KNOWLEDGE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATIENT SELECTION; PHENOTYPE; PRIORITY JOURNAL; PSORIASIS VULGARIS; RISK; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

EID: 47349093732     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2008.16     Document Type: Article

References (12)

1. Campalani E, Arenas M, Marinaki AM, Lewis CM, Barker JNWN, Smith CH (2007) Polymorphisms in folate, pyrimidine, and purine metabolism are associated with efficacy and toxicity of methotrexate in psoriasis. J Invest Dermatol 127:1860-7
2. Choudhuri S, Klaassen CD (2006) Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int J Toxicol 25:231-59
3. Dervieux T, Furst D, Lein DO, Capps R, Smith K, Walsh M et al. (2004) Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 50:2766-74
4. Fredriksson T, Pettersson U (1978) Severe psoriasis - oral therapy with a new retinoid. Dermatologica 157:238-44
5. Griffiths CEM, Barker JNWN (2007) Pathogenesis and clinical features of psoriasis. Lancet 370:263-71
6. Hyde SC, Emsley P, Hartshorn MJ, Mimmack MM, Gileadi U, Pearce SR et al. (1990) Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature 346:362-5
7. Kumagai K, Hiyama K, Oyama T, Maeda H, Kohno N (2003) Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis. Int J Mol Med 11:593-600
8. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL et al. (2005) Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352:2285-93
9. Urano W, Taniguchi A, Yamanaka H, Tanaka E, Nakajima H, Matsuda Y et al. (2002) Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 12:183-90
10. van Ede AE, Laan RF, Blom HJ, Huizinga TW, Haagsma CJ, Giesendorf BA et al. (2001) The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum 44:2525-30
11. Vogel F (1959) Moderne problem der humangenetik. Ergeb Inn Med U Kinderheilk 12:52-125
12. Wessels JA, Kooloos WM, De JR, de Vries-Bouwstra JK, Allaart CF, Linssen A et al. (2006) Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 54:2830-9